contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

C-Rad is active in medical technology. The company conducts the development, manufacturing, and sales of products and solutions in advanced radiation therapy. The business is mainly aimed at clinics that offer radiation treatment, where the company in addition to its core business offers associated installation services and support. The customers are located on a global level and the head office is located in Uppsala.

C-Rad

C-RAD AB (publ), is announcing today that Linda Frölén has been appointed new Chief Financial Officer (CFO). She will take office latest September 30, 2024, and is replacing Jonas Reinhammar...

<div class="mfn-preamble"><p><strong>C-RAD AB (publ), is announcing today that Linda Frölén has been appointed new Chief Financial Officer (CFO). She will take office latest September 30, 2024, and is replacing Jonas Reinhammar, Interim CFO since May 13, 2024.</strong></p></div><div class="mfn-body"><p>Linda Frölén joins C-RAD from Sedana Medical AB (publ.), where she has served as Head of Group Finance since 2021. Her responsibilities have been to oversee the entire finance function. Previously, Linda has had multiple roles within Group finance, e g within life science company Meda AB (publ) and before that many years as auditor at Deloitte in Stockholm.<br>&nbsp;<br>"We are thrilled to welcome Linda to C-RAD. Her extensive experience and broad expertise in financial management and accounting will be invaluable to us. I look forward to working together with Linda and am confident that she will bring significant value through her personality and professional skills." says Cecilia de Leeuw, CEO C-RAD and President.<br>&nbsp;<br>“I am honored and happy to be part of the company in this important growth phase. I look forward working together with a strong and engaged team and to contribute to C-RAD’s successful development, continuing to establish C-RAD’s Surface Guided Radiation Therapy, SGRT, across more clinics and to improve the treatment and quality of life for cancer patients around the world – this feels important to me”, says Linda Frölén.<br>&nbsp;<br>Linda holds a master's degree in business administration from the School of Business, Economics and Law at the University of Gothenburg, with specializations in accounting, corporate finance, and international macroeconomics.</p></div><div class="mfn-footer mfn-contacts mfn-e520b92ae86a"><p><strong class="mfn-heading-1">For further information:</strong></p><hr><p>Cecilia de Leeuw, CEO, +46 (0)795 85 66 77, <a rel="noopener" href="mailto:investors@c-rad.com">investors@c-rad.com</a></p></div><div class="mfn-footer mfn-about mfn-1fc3b360975a"><p><strong class="mfn-heading-1">About C-RAD</strong></p><hr><p>C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.</p><p>C-RAD. Inspiring excellence in cancer treatment.</p><p>C-RAD AB is listed on NASDAQ Stockholm.</p><p>For more information on C-RAD, please visit&nbsp;<a rel="noopener" href="http://www.c-rad.com/">http://www.c-rad.com</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/151b1493-2693-421d-ab01-e6fa22216915/c-rad-appoints-linda-frolen-as-new-cfo.pdf" class="mfn-generated mfn-primary">C-RAD appoints Linda Frölén as new CFO</a></p></div>

C-RAD appoints Linda Frölén as new CFO

Wall Streetin arvostustasoihin verrattuna Eurooppakin näyttää nyt houkuttelevalta

Federal Reserven korkopäätös: Kiire loppui tähän

Lääkekehityssijoittaminen: Arvonluonti yrityskaupoilla ja lisensointisopimuksilla

EKP:n korkopäätös: Keskuspankki ilman rajoitteita

Euroalueen ostopäälliköt: Onks sen jälkeen vielä mäki?

Pysy ajantasalla Inderesin uutiskirjeillä